If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ® (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can I escalate the dose in patients who have a suboptimal response to Omvoh® (mirikizumab-mrkz)?
Eli Lilly and Company does not have any recommendations regarding increasing the mirikizumab dose in patients with suboptimal or loss of response. Please see approved mirikizumab dosing below and in the prescribing information.
Approved Mirikizumab Dosage and Administration for the Treatment of Ulcerative Colitis
Induction Dosing by Intravenous Infusion
The recommended induction dosage of mirikizumab for the treatment of ulcerative colitis is 300 mg administered by intravenous infusion over at least 30 minutes at weeks 0, 4, and 8.1
Maintenance Dosing by Subcutaneous Injection
The recommended maintenance dosage of mirikizumab for the treatment of ulcerative colitis is 200 mg administered by subcutaneous injection, given as 2 consecutive injections of 100 mg each, at week 12, and every 4 weeks thereafter.1
Approved Mirikizumab Dosage and Administration for the Treatment of Crohn's Disease
Induction Dosing by Intravenous Infusion
The recommended induction dosage of mirikizumab for the treatment of Crohn's disease is 900 mg administered by intravenous infusion over at least 90 minutes at weeks 0, 4, and 8.1
Maintenance Dosing by Subcutaneous Injection
The recommended maintenance dosage of mirikizumab for the treatment of Crohn's disease is 300 mg administered by subcutaneous injection, given as 2 consecutive injections of 100 mg and 200 mg, at week 12, and every 4 weeks thereafter.1
Enclosed Prescribing Information
Reference
1Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: January 15, 2025